AstraZeneca Pharma India has received CDSCO permission to import and market Trastuzumab Deruxtecan (Enhertu) for an additional indication. The drug is now cleared in combination with pertuzumab for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer, providing an advanced precision option early in patient care.
BENGALURU — Global biopharmaceutical innovator AstraZeneca Pharma India Limited has secured formal regulatory permission to expand the commercial footprint of its blockbuster precision oncology drug, Trastuzumab Deruxtecan, within the Indian domestic market.
The pharmaceutical manufacturer confirmed via an institutional transaction disclosure submitted to the National Stock Exchange of India (NSE) on Thursday, June 11, 2026, that it has received official import and marketing clearance from the Central Drugs Standard Control Organisation (CDSCO), under the Directorate General of Health Services, Government of India. The newly granted clearance specifically authorizes the import, sale, and distribution of the targeted therapy for a vital first-line indication, offering a major therapeutic advancement for advanced-stage cancer patients across the subcontinent.
Expanding the Frontline Therapeutic Regimen for HER2-Positive Cases
The newly sanctioned regulatory clearance allows AstraZeneca to market Trastuzumab Deruxtecan (distributed globally under the co-developed brand name Enhertu) as a lyophilized powder for concentrate solution in 100 mg/5mL vials. Under the approved clinical parameters, the antibody-drug conjugate (ADC) is now officially indicated in combination with pertuzumab for the first-line treatment of adult patients presenting with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Prior to this additional regulatory milestone, the drug's specialized use inside India was confined strictly to second-line or salvage settings, targeting individuals who had already experienced disease progression on standard anti-HER2 regimens. Moving the precision therapy into the first-line category allows clinical oncologists to deploy the highly potent asset immediately upon advanced diagnosis, aiming to disrupt tumor replication before alternative chemotherapies alter local cell vulnerabilities.
Technical Mechanism of the Antibody-Drug Conjugate
Trastuzumab Deruxtecan operates through a highly specialized "Trojan Horse" delivery system that combines targeted biologics with potent chemotherapy agents. The molecule consists of a humanized anti-HER2 monoclonal antibody structurally linked to a topoisomerase I inhibitor payload via a cleavable peptide linker.
This structural configuration ensures that the cytotoxic payload is directed precisely to cells overexpressing the HER2 receptor, minimizing systemic damage to healthy tissues. Clinical data from global trials reveals that this selective destruction mechanism significantly improves progression-free survival (PFS) and overall survival outcomes compared to traditional, non-targeted chemotherapy options.
Addressing India’s Escalating Breast Cancer Burden
The expansion of precision oncology pipelines comes at a critical juncture for domestic healthcare networks. Statistics tracked by the World Health Organization (WHO) indicate that breast cancer stands as the most frequently diagnosed malignancy among women across India, with nationwide incidence rates surging by nearly 40% over the past 25 years.
Due to low baseline screening awareness and delayed initial diagnostic consultations, a substantial percentage of Indian patients are identified only after the disease has reached an advanced or metastatic stage. The availability of targeted first-line therapies helps bridge a critical therapeutic gap, providing domestic medical teams with an advanced toolkit to manage aggressive solid tumors more effectively.
Official Sources Section
Regulatory milestones, asset specifications, clinical indications, and distribution permissions are prepared in strict accordance with statutory corporate declarations submitted to the National Stock Exchange of India (NSE) and the BSE under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements. Additional medical parameters are verified against historical data sheets maintained by the Central Drugs Standard Control Organisation (CDSCO).
Quote Section
The company’s corporate compliance wing noted that the receipt of the regulatory green light represents a vital step toward scaling advanced healthcare accessibility across the country.
According to formal stock exchange disclosures signed by Tanya Sanish, Company Secretary and Compliance Officer at AstraZeneca Pharma India Limited:
"On June 10, 2026, AstraZeneca Pharma India Limited received permission from the Central Drugs Standard Control Organization to import for sale and distribution of Trastuzumab deruxtecan 100 mg/5mL vial lyophilized powder for concentrate for solution for infusion (Brand name: Enhertu®) for an additional indication. The receipt of this permission paves the way for marketing the therapy in India for the specified additional indication, subject to related statutory approvals."
Commenting on the clinical progression of the therapy, domestic oncology research leads added:
"Bringing an antibody-drug conjugate into the first-line treatment space for metastatic HER2-positive breast cancer marks a paradigm shift in precision medicine. By pairing this targeted agent with pertuzumab early in the treatment cycle, we can significantly delay disease progression and provide a superior quality of life for patients facing advanced diagnoses."
Why It Matters
For advanced cancer patients and their families, this first-line clearance removes a significant administrative and clinical obstacle, allowing them to access state-of-the-art targeted therapies immediately rather than waiting for initial treatments to fail.
From an investment and healthcare market perspective, AstraZeneca's successful expansion of its specialty medicine pipeline reinforces its leadership in the precision oncology sector. This development is expected to drive long-term revenue visibility and attract higher institutional investor interest toward the company's domestic equity structure.
Key Facts at a Glance
New Nod: AstraZeneca India secured CDSCO permission to import and distribute Trastuzumab Deruxtecan for an additional frontline indication.
Target Treatment: The drug is now indicated in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
The Platform: Distributed under the brand name Enhertu, the medication is imported as a 100 mg/5mL vial lyophilized powder.
Market Significance: This expansion marks a major shift from later-stage salvage therapy to an immediate, first-line precision oncology option.
FAQ Section
What is the primary medical benefit of the new first-line indication for Enhertu?
The first-line indication allows doctors to prescribe this targeted antibody-drug conjugate as the initial treatment immediately upon an advanced diagnosis, helping to suppress tumor growth before the cancer develops resistance to other therapies.
How does an antibody-drug conjugate (ADC) differ from traditional chemotherapy?
Traditional chemotherapy circulates throughout the entire body, damaging both healthy and cancerous cells. An ADC uses a targeted monoclonal antibody to locate and bind directly to specific cancer receptors, releasing its cancer-killing payload inside the tumor cell to minimize systemic side effects.
Are there any remaining regulatory steps before the drug becomes available for this indication?
The formal approval from the CDSCO establishes the foundational permission for import and sale. Commercial availability across hospital networks will proceed following the finalization of internal distribution logistics and related local statutory clearances.
Source: National Stock Exchange of India (NSE) Corporate Archive, Central Drugs Standard Control Organisation (CDSCO), AstraZeneca India Investor Relations Division, World Health Organization Global Cancer Observatory.
